| The role of the fallopian tube in the origin of ovarian cancer BK Erickson, MG Conner, CN Landen Jr American journal of obstetrics and gynecology 209 (5), 409-414, 2013 | 356 | 2013 |
| Changes in incidence and indications of tonsillectomy and adenotonsillectomy, 1970-2005 BK Erickson, DR Larson, JL St. Sauver, RA Meverden, LJ Orvidas Otolaryngology—Head and Neck Surgery 140 (6), 894-901, 2009 | 266 | 2009 |
| Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer ZC Dobbin, AA Katre, AD Steg, BK Erickson, MM Shah, RD Alvarez, ... Oncotarget 5 (18), 8750, 2014 | 144 | 2014 |
| Cervical cancer screening: evidence behind the guidelines BF Lees, BK Erickson, WK Huh American journal of obstetrics and gynecology 214 (4), 438-443, 2016 | 139 | 2016 |
| Human papillomavirus: what every provider should know BK Erickson, RD Alvarez, WK Huh American journal of obstetrics and gynecology 208 (3), 169-175, 2013 | 99 | 2013 |
| New insights into cervical cancer screening JD Boone, BK Erickson, WK Huh Journal of gynecologic oncology 23 (4), 282, 2012 | 93 | 2012 |
| Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center BK Erickson, JY Martin, MM Shah, JM Straughn Jr, CA Leath III Gynecologic oncology 133 (2), 142-146, 2014 | 70 | 2014 |
| Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era? A Subramaniam, JM Fauci, KE Schneider, JM Whitworth, BK Erickson, ... Journal of lower genital tract disease 15 (2), 110-113, 2011 | 64 | 2011 |
| Enhanced recovery program and length of stay after laparotomy on a gynecologic oncology service: a randomized controlled trial EL Dickson, E Stockwell, MA Geller, RI Vogel, SA Mullany, R Ghebre, ... Obstetrics & Gynecology 129 (2), 355-362, 2017 | 62 | 2017 |
| Uterine serous carcinoma: key advances and novel treatment approaches JS Ferriss, BK Erickson, IM Shih, AN Fader International Journal of Gynecologic Cancer 31 (8), 2021 | 61 | 2021 |
| Feasibility of complete salpingectomy compared with standard postpartum tubal ligation at cesarean delivery: a randomized controlled trial A Subramaniam, CT Blanchard, BK Erickson, J Szychowski, CA Leath, ... Obstetrics & Gynecology 132 (1), 20-27, 2018 | 61 | 2018 |
| Diabetes mellitus and ovarian cancer: more complex than just increasing risk MM Shah, BK Erickson, T Matin, G McGwin Jr, JY Martin, LB Daily, ... Gynecologic oncology 135 (2), 273-277, 2014 | 58 | 2014 |
| Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study BK Erickson, O Najjar, S Damast, A Blakaj, J Tymon-Rosario, M Shahi, ... Gynecologic oncology 159 (1), 17-22, 2020 | 56 | 2020 |
| The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer AA Serebrenik, PP Argyris, MC Jarvis, WL Brown, M Bazzaro, RI Vogel, ... Clinical Cancer Research 26 (13), 3397-3407, 2020 | 52 | 2020 |
| Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer BK Erickson, I Kinde, ZC Dobbin, Y Wang, JY Martin, RD Alvarez, ... Obstetrics & Gynecology 124 (5), 881-885, 2014 | 52 | 2014 |
| An innovative medical school curriculum to address human papillomavirus vaccine hesitancy AM Schnaith, EM Evans, C Vogt, AM Tinsay, TE Schmidt, KM Tessier, ... Vaccine 36 (26), 3830-3835, 2018 | 48 | 2018 |
| The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial PA Argenta, KV Ballman, MA Geller, LF Carson, R Ghebre, SA Mullany, ... Gynecologic oncology 144 (1), 159-166, 2017 | 46 | 2017 |
| Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies BK Erickson, B Zeybek, AD Santin, AN Fader Current Opinion in Obstetrics and Gynecology 32 (1), 57-64, 2020 | 42 | 2020 |
| Update on vaccination clinical trials for HPV-related disease BK Erickson, EE Landers, WK Huh Clinical therapeutics 36 (1), 8-16, 2014 | 40 | 2014 |
| The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction A Subramaniam, BD Einerson, CT Blanchard, BK Erickson, J Szychowski, ... Gynecologic oncology 152 (1), 127-132, 2019 | 32 | 2019 |
